abstract |
Arylpyrazine compounds are provided, which include arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, which include human CRF1 receptors. Thus, the invention includes methods for treating disorders and diseases related to CRF1 receptors, which include disorders of CNS-related diseases, particularly disorders and affective diseases, and acute and chronic neurological disorders and diseases. |